SECOND TEAM

Richard Yeh  Citi

Richard Yeh makes an impressive debut in second place. Investors admire the Citi analyst for his “Western perspective of China pharmaceuticals, well-articulated arguments and methodical data analysis,” as one money manager puts it. Yeh downgraded the American depositary receipts of Mindray Medical International from buy to hold in November, at $27.47, citing rising competition for the Shenzhen, Guangdong–based manufacturer’s medical devices. The stock slipped 2.7 percent, to $26.73, through April. During the same period the sector fell 10.7 percent.